The Netherlands Cancer Institute (NKI) and to-BBB to collaborate on brain delivery of anti-cancer drugs
to-BBB and Dr. Olaf van Tellingen from the Department of clinical chemistry of The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (NKI-AVL) will collaborate on the development of a potential new therapy for brain tumors.
Chemotherapeutic treatment options for primary and metastatic brain cancer patients are limited and overall prognoses are dismal. To a large extend this is due to the neuroprotective role of the blood-brain barrier (BBB), limiting the safe delivery of many anti-cancer drugs to their disease target in the brain.
The research group of Dr. van Tellingen has developed a series of advanced experimental models to address key topics in the development of new therapies for Brain Tumors, including their transport across the blood-brain barrier.
to-BBB’s G-Technology™ is designed for safe brain delivery of different classes of drugs by formulating these drugs into proprietary glutathione coated stealth liposomes. The G-Technology™ has shown proof of concept in several disease models, based on which the research group of Dr. van Tellingen and to-BBB will join forces to develop brain-targeted liposomes with encapsulated anti-cancer drugs.
Most read news

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Coupled Proteins - How human cells react to external signals and further process them

'Trojan horse' anticancer drug disguises itself as fat - Promising system delivers chemo drug straight into tumors with fewer side effects
Oncothyreon announces issuance of patent for PX-867
Hypocapnia
UCB strengthens strategic alliance with WILEX - UCB's position as a strategic investor now represents 18% of WILEX shares
Cardio3 BioSciences Establishes US Subsidiary in Rochester, MN
